-DOCSTART- -X- O
Subtype -X- _ O
B -X- _ O
coxsackieviruses -X- _ O
( -X- _ O
CVB -X- _ O
) -X- _ O
represent -X- _ O
the -X- _ O
most -X- _ O
commonly -X- _ O
identified -X- _ O
infectious -X- _ O
agents -X- _ O
associated -X- _ O
with -X- _ O
acute -X- _ O
and -X- _ O
chronic -X- _ O
myocarditis -X- _ O
, -X- _ O
with -X- _ O
CVB3 -X- _ O
being -X- _ O
the -X- _ O
most -X- _ O
common -X- _ O
variant. -X- _ O
Damage -X- _ O
to -X- _ O
the -X- _ O
heart -X- _ O
is -X- _ O
induced -X- _ O
both -X- _ O
directly -X- _ O
by -X- _ O
virally -X- _ O
mediated -X- _ O
cell -X- _ O
destruction -X- _ O
and -X- _ O
indirectly -X- _ O
due -X- _ O
to -X- _ O
the -X- _ O
immune -X- _ O
and -X- _ O
autoimmune -X- _ O
processes -X- _ O
reacting -X- _ O
to -X- _ O
virus -X- _ O
infection. -X- _ O
This -X- _ O
review -X- _ O
addresses -X- _ O
antiviral -X- _ B-Intervention
therapeutics -X- _ I-Intervention
for -X- _ O
cardiac -X- _ B-Patient
coxsackievirus -X- _ I-Patient
infections -X- _ I-Patient
discovered -X- _ O
over -X- _ O
the -X- _ O
last -X- _ O
25 -X- _ O
years. -X- _ O
One -X- _ O
group -X- _ O
represents -X- _ O
pharmacologically -X- _ B-Intervention
active -X- _ I-Intervention
low -X- _ I-Intervention
molecular -X- _ I-Intervention
weight -X- _ I-Intervention
substances -X- _ I-Intervention
that -X- _ O
inhibit -X- _ B-Outcome
virus -X- _ I-Outcome
uptake -X- _ I-Outcome
by -X- _ I-Outcome
binding -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
virus -X- _ I-Outcome
capsid -X- _ I-Outcome
( -X- _ I-Outcome
e.g. -X- _ I-Outcome
, -X- _ I-Outcome
pleconaril -X- _ I-Outcome
) -X- _ I-Outcome
or -X- _ I-Outcome
inactivate -X- _ I-Outcome
viral -X- _ I-Outcome
proteins -X- _ I-Outcome
( -X- _ I-Outcome
e.g. -X- _ I-Outcome
, -X- _ I-Outcome
NO- -X- _ I-Outcome
metoprolol -X- _ I-Outcome
and -X- _ I-Outcome
ribavirin -X- _ I-Outcome
) -X- _ I-Outcome
or -X- _ I-Outcome
inhibit -X- _ I-Outcome
cellular -X- _ I-Outcome
proteins -X- _ I-Outcome
which -X- _ I-Outcome
are -X- _ I-Outcome
essential -X- _ I-Outcome
for -X- _ I-Outcome
viral -X- _ I-Outcome
replication -X- _ I-Outcome
( -X- _ I-Outcome
e.g. -X- _ I-Outcome
, -X- _ I-Outcome
ubiquitination -X- _ I-Outcome
inhibitors -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
A -X- _ O
second -X- _ O
important -X- _ O
group -X- _ O
of -X- _ O
substances -X- _ O
are -X- _ O
interferons. -X- _ B-Intervention
They -X- _ O
have -X- _ O
antiviral -X- _ B-Outcome
but -X- _ I-Outcome
also -X- _ I-Outcome
immunomodulating -X- _ I-Outcome
activities. -X- _ I-Outcome
The -X- _ O
third -X- _ O
and -X- _ O
most -X- _ O
recently -X- _ O
discovered -X- _ O
group -X- _ O
includes -X- _ O
biological -X- _ B-Intervention
and -X- _ I-Intervention
cellular -X- _ I-Intervention
therapeutics. -X- _ I-Intervention
Soluble -X- _ B-Outcome
receptor -X- _ I-Outcome
analogues -X- _ I-Outcome
( -X- _ I-Outcome
e.g. -X- _ I-Outcome
, -X- _ I-Outcome
sCAR-Fc -X- _ I-Outcome
) -X- _ I-Outcome
bind -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
virus -X- _ I-Outcome
capsid -X- _ I-Outcome
and -X- _ I-Outcome
block -X- _ I-Outcome
virus -X- _ I-Outcome
uptake. -X- _ I-Outcome
Small -X- _ I-Outcome
interfering -X- _ I-Outcome
RNAs -X- _ I-Outcome
, -X- _ I-Outcome
short -X- _ I-Outcome
hairpin -X- _ I-Outcome
RNAs -X- _ I-Outcome
and -X- _ I-Outcome
antisense -X- _ I-Outcome
oligonucleotides -X- _ I-Outcome
bind -X- _ I-Outcome
to -X- _ I-Outcome
and -X- _ I-Outcome
led -X- _ I-Outcome
to -X- _ I-Outcome
degradation -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
viral -X- _ I-Outcome
RNA -X- _ I-Outcome
genome -X- _ I-Outcome
or -X- _ I-Outcome
cellular -X- _ I-Outcome
RNAs -X- _ I-Outcome
, -X- _ I-Outcome
thereby -X- _ I-Outcome
preventing -X- _ I-Outcome
their -X- _ I-Outcome
translation -X- _ I-Outcome
and -X- _ I-Outcome
viral -X- _ I-Outcome
replication. -X- _ I-Outcome
Most -X- _ O
recently -X- _ O
mesenchymal -X- _ O
stem -X- _ O
cell -X- _ O
transplantation -X- _ O
has -X- _ O
been -X- _ O
shown -X- _ B-Outcome
to -X- _ I-Outcome
possess -X- _ I-Outcome
antiviral -X- _ I-Outcome
activity -X- _ I-Outcome
in -X- _ I-Outcome
CVB3 -X- _ I-Outcome
infections. -X- _ I-Outcome
Taken -X- _ O
together -X- _ O
, -X- _ O
a -X- _ O
number -X- _ O
of -X- _ O
antiviral -X- _ O
therapeutics -X- _ O
has -X- _ O
been -X- _ O
developed -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
myocardial -X- _ O
CVB -X- _ O
infection -X- _ O
in -X- _ O
recent -X- _ O
years. -X- _ O
In -X- _ O
addition -X- _ O
to -X- _ O
low -X- _ O
molecular -X- _ O
weight -X- _ O
inhibitors -X- _ O
, -X- _ O
biological -X- _ O
therapeutics -X- _ O
have -X- _ O
become -X- _ O
promising -X- _ O
anti-viral -X- _ O
agents -X- _ O
. -X- _ O

